<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04849325</url>
  </required_header>
  <id_info>
    <org_study_id>IBS-Titan-01</org_study_id>
    <nct_id>NCT04849325</nct_id>
  </id_info>
  <brief_title>IBS Titan vs. PTA in Patients With Infrapopliteal Arterial Stenosis or Occlusive Disease</brief_title>
  <acronym>GENIUS</acronym>
  <official_title>A Prospective, Multi-Center, Randomized Trial Comparing the IBS Titan™ Sirolimus-Eluting Iron Bioresorbable Peripheral Scaffold System vs. Standard Balloon Angioplasty for Treatment of Below-the-Knee Arteries: GENIUS TRIAL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotyx Medical (Shenzhen) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biotyx Medical (Shenzhen) Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, multi-center, randomized trial to assess the safety and effectiveness of&#xD;
      Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System (IBS Titan™) in treating&#xD;
      patients with infrapopliteal arterial stenosis or occlusive disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Patency Rate</measure>
    <time_frame>180 days</time_frame>
    <description>Defined as freedom from total occlusion of target lesion and clinically driven target lesion revascularization (CD-TLR) of target lesion, and freedom from major amputation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>30 days, 180 days, 365 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Clinically-driven Target Vessel Revascularization (CD-TLR)</measure>
    <time_frame>30 days, 180 days, 365 days</time_frame>
    <description>CD-TLR is defined as any TLR of target lesions associated with Rutherford category exacerbation and/or increasing in the size of preexisting wounds and/or the occurrence of new wounds.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of major amputation</measure>
    <time_frame>30 days, 180 days, 365 days</time_frame>
    <description>Unplanned amputation of the lower limb above the ankle on the target lesion side</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Device Success</measure>
    <time_frame>Immediately after the procedure</time_frame>
    <description>Device success is defined on a per device basis, as the achievement of successful delivery, deployment of stent at the intended infrapopliteal target site(s) and successful withdrawal of the delivery catheter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Participants with Technical Success</measure>
    <time_frame>Immediately after the procedure</time_frame>
    <description>Defined as restoration of blood flow in the target vessel and angiogram indicates the residual stenosis &lt;50%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Participants with Procedural Success</measure>
    <time_frame>Immediately after the procedure</time_frame>
    <description>Defined as the combination of technical success, device success, and absence of procedural complications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late Lumen Loss</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Target lesion restenosis</measure>
    <time_frame>30 days, 180 days, 365 days</time_frame>
    <description>Defined as a reduction in the luminal diameter &gt;50% by angiography or CTA within the treated lesion plus the 5-mm segments proximal and distal to it or, as a peak systolic velocity ratio (PSVR) &gt;2.4 by DUS.&#xD;
Note 1: Doppler ultrasound will be performed at 30 days and 365 days, DSA angiography will be performed 180 days.&#xD;
Note 2: If the patient presented with CD-TLR in advance, i.e. the patient reached the endpoint in advance, the restenosis before reintervention was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ankle-brachial index (ABI) compared to baseline (before treatment)</measure>
    <time_frame>30 days, 180 days, 365 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Rutherford-Becker category compared to baseline (before treatment)</measure>
    <time_frame>30 days, 180 days, 365 days</time_frame>
    <description>Categories and Clinical Description (higher scores mean a worse outcome):&#xD;
Category 0 = Asymptomatic, no hemodynamically significant occlusive disease, Category 1 = Mild claudication, Category 2 = Moderate claudication, Category 3 = Severe claudication, Category 4 = Ischemic rest pain, Category 5 = Minor tissue loss, non-healing ulcer, or focal gangrene with diffuse pedal ischemia, Category 6 = Major tissue loss, extending above transmetatarsal level, functional foot no longer salvageable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wound healing rate of ulcer patients</measure>
    <time_frame>30 days, 180 days, 365 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Critical Limb Ischemia (CLI)</condition>
  <arm_group>
    <arm_group_label>IBS Titan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Percutaneous Transluminal Angioplasty (PTA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System (IBS Titan™)</intervention_name>
    <description>Subjects in this arm will be treated with IBS Titan™.</description>
    <arm_group_label>IBS Titan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Percutaneous Transluminal Angioplasty (PTA) Device</intervention_name>
    <description>Subjects in this arm will be treated with PTA device.</description>
    <arm_group_label>Percutaneous Transluminal Angioplasty (PTA)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients must between 18 and 85 years old, without gender limit.&#xD;
&#xD;
          2. Patients who can understand the purpose of the trial, voluntarily participate in and&#xD;
             sign the informed consent form, and complete the 1-year follow-up.&#xD;
&#xD;
          3. Subject has lower extremity atherosclerotic occlusive disease with symptomatic&#xD;
             Critical Limb Ischemia (CLI).&#xD;
&#xD;
          4. Rutherford Becker Clinical Category 3-5.&#xD;
&#xD;
          5. The target lesion is below the popliteal artery (including bifurcation).&#xD;
&#xD;
          6. The target lesion is located in the proximal 2/3 of native infrapopliteal vessels or&#xD;
             tibiofibular trunk.&#xD;
&#xD;
          7. The target lesion stenosis is ≥70% or occlusion of no more than two infrapopliteal&#xD;
             arteries (including the anterior and/or posterior tibial and/or peroneal artery and/or&#xD;
             tibiofibular trunk).&#xD;
&#xD;
          8. The length of target lesion is ≤200mm, which could be covered by no more than two&#xD;
             stents, with vessel diameter of 2.25-4.25 mm.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Severe renal insufficiency, hepatic dysfunction (Cr&gt;2 times of normal limit or renal&#xD;
             dialysis, ALT or AST &gt; 5 times of normal limit).&#xD;
&#xD;
          2. Surgery in target vessel before treatment.&#xD;
&#xD;
          3. Volume reduction surgery in target vessel before treatment.&#xD;
&#xD;
          4. Thrombosis in target vessel, or acute thrombosis requiring thrombolysis and&#xD;
             thrombectomy.&#xD;
&#xD;
          5. Systematic coagulation disorder or hypercoagulability.&#xD;
&#xD;
          6. Lower extremity arteries surgery or thrombolytic therapy in the ipsilateral extremity&#xD;
             in the past 6 weeks.&#xD;
&#xD;
          7. Stroke occurs within 3 months before surgery, or stroke occurs with severe hemiplegia&#xD;
             aphasia sequelae more than 3 months before treatment.&#xD;
&#xD;
          8. Acute myocardial infarction or angina pectoris within 30 days before treatment.&#xD;
&#xD;
          9. In-stent restenosis.&#xD;
&#xD;
         10. Guide wire cannot pass target lesion.&#xD;
&#xD;
         11. Previously treated with drug eluting balloon within 1 year before treatment.&#xD;
&#xD;
         12. More than two infrapopliteal arteries needed treatment.&#xD;
&#xD;
         13. The inflow tract (including ipsilateral iliac artery, femoral artery, popliteal&#xD;
             artery) has lumen stenosis &gt;30% with or without intervention.&#xD;
&#xD;
         14. The inflow tract (including ipsilateral iliac artery, femoral artery, popliteal&#xD;
             artery) has &gt; 150 mm stenosis or occlusion before treatment.&#xD;
&#xD;
         15. Aneurysm of lower extremity artery.&#xD;
&#xD;
         16. Thromboangiitis obliterans (Buerger's disease).&#xD;
&#xD;
         17. Significant (≥ 50% stenosis) lesion in a distal outflow artery that would be perfused&#xD;
             by the target vessel and that requires treatment at the time of the index procedure.&#xD;
&#xD;
         18. Patients known to be allergic to aspirin, heparin, Plavix, contrast agents, Sirolimus,&#xD;
             poly lactic acid polymer, iron, zinc and their degradation product, and those who&#xD;
             cannot tolerate postoperative dual anti-platelet therapy.&#xD;
&#xD;
         19. Patients who have a history of disease related to iron overload or iron disorder, such&#xD;
             as hereditary hemochromatosis, etc.&#xD;
&#xD;
         20. Patients who are participating in another clinical trial that has not yet completed&#xD;
             its primary endpoint.&#xD;
&#xD;
         21. Pregnant or those who plan pregnancy during the clinical investigation follow-up&#xD;
             period.&#xD;
&#xD;
         22. Angiography suggests intraoperative thromboendarterectomy, percutaneous transluminal&#xD;
             rotational atherectomy or laser therapy are needed.&#xD;
&#xD;
         23. Patients have life expectancy ≤ 1 year.&#xD;
&#xD;
         24. Patients who are not suitable for participating the trial judged by investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ying Xia</last_name>
    <phone>86 13760184511</phone>
    <email>xiaying@lifetechmed.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Anzhen Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <investigator>
      <last_name>Zhong Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <investigator>
      <last_name>Yongjun Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Tsinghua Changgung Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <investigator>
      <last_name>Weiwei Wu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <investigator>
      <last_name>Yuehong Zheng</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <investigator>
      <last_name>Yinghua Zou</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <investigator>
      <last_name>Xiaoming Zhang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <investigator>
      <last_name>Xuan Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>People's Liberation Army General Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <investigator>
      <last_name>Wei Guo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xiyuan Hospital, China Academy of Chinese Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <investigator>
      <last_name>Baixi Zhuang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xuanwu Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <investigator>
      <last_name>Lianrui Guo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First People's Hospital of Changzhou</name>
      <address>
        <city>Changzhou</city>
        <country>China</country>
      </address>
    </facility>
    <investigator>
      <last_name>Yunfeng Zhu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
    <investigator>
      <last_name>Yu Zhao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Dalian Medical University</name>
      <address>
        <city>Dalian</city>
        <country>China</country>
      </address>
    </facility>
    <investigator>
      <last_name>Feng Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Fujian Medical University</name>
      <address>
        <city>Fuzhou</city>
        <country>China</country>
      </address>
    </facility>
    <investigator>
      <last_name>Pingfan Guo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangxi Medical University</name>
      <address>
        <city>Guangxi</city>
        <country>China</country>
      </address>
    </facility>
    <investigator>
      <last_name>Xiao Qin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital, Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <investigator>
      <last_name>Hongkun Zhang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <country>China</country>
      </address>
    </facility>
    <investigator>
      <last_name>Weimin Zhou</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
    <investigator>
      <last_name>Xiaoqiang Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital with Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
    <investigator>
      <last_name>Xiwei Zhang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Renji Hospital, Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <investigator>
      <last_name>Lan Zhang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <investigator>
      <last_name>Xinwu Lu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <investigator>
      <last_name>Weiguo Fu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shengjing Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <country>China</country>
      </address>
    </facility>
    <investigator>
      <last_name>Zhaoyu Liu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <country>China</country>
      </address>
    </facility>
    <investigator>
      <last_name>Wei Bi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Second Hospital of Shanxi Medical University</name>
      <address>
        <city>Taiyuan</city>
        <country>China</country>
      </address>
    </facility>
    <investigator>
      <last_name>Honglin Dong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>General Hospital of Tianjin Medical University</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
    <investigator>
      <last_name>Xiangchen Dai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjin 4th Centre Hospital</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
    <investigator>
      <last_name>Yidong Liu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henan Provincial People's Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <country>China</country>
      </address>
    </facility>
    <investigator>
      <last_name>Shuiting Zhai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <country>China</country>
      </address>
    </facility>
    <investigator>
      <last_name>Zhen Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 14, 2021</study_first_submitted>
  <study_first_submitted_qc>April 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2021</study_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

